These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12370908)

  • 1. Solid-phase synthesis and biological evaluation of a pepticinnamin E library.
    Thutewohl M; Kissau L; Popkirova B; Karaguni IM; Nowak T; Bate M; Kuhlmann J; Müller O; Waldmann H
    Angew Chem Int Ed Engl; 2002 Oct; 41(19):3616-20; 3516. PubMed ID: 12370908
    [No Abstract]   [Full Text] [Related]  

  • 2. Design, synthesis, and characterization of peptide-based rab geranylgeranyl transferase inhibitors.
    Tan KT; Guiu-Rozas E; Bon RS; Guo Z; Delon C; Wetzel S; Arndt S; Alexandrov K; Waldmann H; Goody RS; Wu YW; Blankenfeldt W
    J Med Chem; 2009 Dec; 52(24):8025-37. PubMed ID: 19894725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase.
    Burns CJ; Guitton JD; Baudoin B; Lelièvre Y; Duchesne M; Parker F; Fromage N; Commerçon A
    J Med Chem; 1997 Jun; 40(12):1763-7. PubMed ID: 9191950
    [No Abstract]   [Full Text] [Related]  

  • 4. C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.
    McNamara DJ; Dobrusin E; Leonard DM; Shuler KR; Kaltenbronn JS; Quin J; Bur S; Thomas CE; Doherty AM; Scholten JD; Zimmerman KK; Gibbs BS; Gowan RC; Latash MP; Leopold WR; Przybranowski SA; Sebolt-Leopold JS
    J Med Chem; 1997 Oct; 40(21):3319-22. PubMed ID: 9341905
    [No Abstract]   [Full Text] [Related]  

  • 5. Solid-phase synthesis of a pepticinnamin E library.
    Thutewohl M; Waldmann H
    Bioorg Med Chem; 2003 Jun; 11(12):2591-615. PubMed ID: 12757726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of mono- and bisubstrate inhibitors of protein farnesyltransferase and inducers of apoptosis from a pepticinnamin E library.
    Thutewohl M; Kissau L; Popkirova B; Karaguni IM; Nowak T; Bate M; Kuhlmann J; Müller O; Waldmann H
    Bioorg Med Chem; 2003 Jun; 11(12):2617-26. PubMed ID: 12757727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
    Anthony NJ; Gomez RP; Schaber MD; Mosser SD; Hamilton KA; O'Neil TJ; Koblan KS; Graham SL; Hartman GD; Shah D; Rands E; Kohl NE; Gibbs JB; Oliff AI
    J Med Chem; 1999 Aug; 42(17):3356-68. PubMed ID: 10464022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
    Williams TM; Ciccarone TM; MacTough SC; Bock RL; Conner MW; Davide JP; Hamilton K; Koblan KS; Kohl NE; Kral AM; Mosser SD; Omer CA; Pompliano DL; Rands E; Schaber MD; Shah D; Wilson FR; Gibbs JB; Graham SL; Hartman GD; Oliff AI; Smith RL
    J Med Chem; 1996 Mar; 39(7):1345-8. PubMed ID: 8691462
    [No Abstract]   [Full Text] [Related]  

  • 9. Aromatic oligopeptides with chlorambucil moiety--synthesis and biological evaluation.
    Bartulewicz D
    Acta Pol Pharm; 2005; 62(6):451-5. PubMed ID: 16583984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-guided development of selective RabGGTase inhibitors.
    Bon RS; Guo Z; Stigter EA; Wetzel S; Menninger S; Wolf A; Choidas A; Alexandrov K; Blankenfeldt W; Goody RS; Waldmann H
    Angew Chem Int Ed Engl; 2011 May; 50(21):4957-61. PubMed ID: 21520375
    [No Abstract]   [Full Text] [Related]  

  • 12. Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
    Lombardo LJ; Camuso A; Clark J; Fager K; Gullo-Brown J; Hunt JT; Inigo I; Kan D; Koplowitz B; Lee F; McGlinchey K; Qian L; Ricca C; Rovnyak G; Traeger S; Tokarski J; Williams DK; Wu LI; Zhao Y; Manne V; Bhide RS
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1895-9. PubMed ID: 15780629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics.
    Koblan KS; Kohl NE; Omer CA; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A; Gibbs JB
    Biochem Soc Trans; 1996 Aug; 24(3):688-92. PubMed ID: 8878827
    [No Abstract]   [Full Text] [Related]  

  • 14. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by 5-cinnamoylaminobenzophenones.
    Mitsch A; Wissner P; Böhm M; Silber K; Klebe G; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2004 Sep; 337(9):493-501. PubMed ID: 15362122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New class of azaheptapyridine FPT inhibitors as potential cancer therapy agents.
    Zhu HY; Desai J; Cooper AB; Wang J; Rane DF; Kirschmeier P; Strickland C; Liu M; Nomeir AA; Girijavallabhan VM
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1228-31. PubMed ID: 24462667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides.
    Mitsch A; Wissner P; Silber K; Haebel P; Sattler I; Klebe G; Schlitzer M
    Bioorg Med Chem; 2004 Sep; 12(17):4585-600. PubMed ID: 15358286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, pharmacological evaluation, and molecular modeling studies of novel peptidic CAAX analogues as farnesyl-protein-transferase inhibitors.
    Santagada V; Caliendo G; Severino B; Lavecchia A; Perissutti E; Fiorino F; Zampella A; Sepe V; Califano D; Santelli G; Novellino E
    J Med Chem; 2006 Mar; 49(6):1882-90. PubMed ID: 16539374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy.
    O'Connor SJ; Barr KJ; Wang L; Sorensen BK; Tasker AS; Sham H; Ng SC; Cohen J; Devine E; Cherian S; Saeed B; Zhang H; Lee JY; Warner R; Tahir S; Kovar P; Ewing P; Alder J; Mitten M; Leal J; Marsh K; Bauch J; Hoffman DJ; Sebti SM; Rosenberg SH
    J Med Chem; 1999 Sep; 42(18):3701-10. PubMed ID: 10479301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total synthesis of the putative structure of lucentamycin A.
    Pal U; Ranatunga S; Ariyarathna Y; Del Valle JR
    Org Lett; 2009 Nov; 11(22):5298-301. PubMed ID: 19863114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broad-based quantitative structure-activity relationship modeling of potency and selectivity of farnesyltransferase inhibitors using a Bayesian regularized neural network.
    Polley MJ; Winkler DA; Burden FR
    J Med Chem; 2004 Dec; 47(25):6230-8. PubMed ID: 15566293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.